AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04673656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BKR-017
Description: Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
Study NCT04673656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BKR-017
Description: Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
Study NCT06028334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetUp&Go
Description: A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.
Study NCT06028334 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GetUp&Go with 10-Week Delay
Description: No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp\&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
Study NCT05032742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth parenting stress app
Description: mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
Study NCT06514378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.
Study NCT05021289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: guided imagery
Study NCT04970472 — intervention group
Intervention type: BIOLOGICAL
Intervention: collection of blood, urines, stool and tumor samples
Description: blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
Study NCT04984317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxin A
Description: One-time injection of 100U BOTOX
Study NCT06648460 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Effort-based Decision-Making Task
Description: Virtual Reality-based multi-stage task in which individuals must explore distinct rooms in a virtual environment that vary in the amount of effort (walking) and reward (points) they receive.
Study NCT05749068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapScan intestinal sampling device
Description: CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
Study NCT06619938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness With Biofeedback
Description: The intervention includes two weekly 90-minute sessions of brief mindfulness training, covering mindfulness practices, psychoeducation on caregiving, and group sharing. After the first session, participants receive a wearable device for biofeedback on RR, HR, HRV, EDA, and sleep patterns to support mindfulness practice and reduce stress. A 30-minute session teaches caregivers how to use the devices and understand the parameters. The study uses Fitbit Sense with Fitbit apps, employing PPG sensors. The Fitbit Sense connects to smartphones with the apps installed. Caregivers can: (1) view real-time RR, HR, HRV, and EDA on the device and trends on their phone; (2) receive mindfulness practice reminders; (3) access audio coaching; (4) set personal goals (e.g., 30 minutes of daily practice); (5) track practice duration; (6) rate daily stress; and (7) review sleep quality. After the second session, caregivers practice mindfulness for 30 minutes daily over eight weeks.
Study NCT06619938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Without Biofeedback
Description: The control group will receive two weekly sessions of brief mindfulness training, the same as the intervention group. After the 1st brief mindfulness training, the control group will receive a 30-minute briefing session on goal setting for mindfulness practice. Each caregiver will be asked to develop an action plan for continuous mindfulness practice. A mindfulness therapist will also discuss the challenges and solutions for developing a habit of mindfulness practice with the caregivers in the second session. Caregivers in the control group will be advised to practice mindfulness daily for 30 minutes over the course of eight weeks.
Study NCT06621667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis
Description: diaphragmatic myofascial release
Study NCT06621667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy exercises for hyperkyphosis
Description: traditional physical therapy exercises for hyperkyphosis
Study NCT06620341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: drug education
Description: * Training: Train emergency doctors every month on how to use antibiotic infusion reasonably; The prescription, cancellation, or method of use of antibiotics is decided by doctors.~  * Implementation of intervention cards: When the C-reactive protein (CRP) of patients is exceed 10mg/L, the doctor should determine whether to use antibiotics based on the clinical status of patients.~    * Promotion: Promote reasonably use of intravenous antibiotics through public accounts and posters.~      * Patient education: Distribute educational flyers to patients about how to use antibiotics reasonably.
Study NCT06623305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Light therapy will be administered using the cluster probe on the external cheeks bilaterally and intraorally using the lollipop probe for patients ≥7 years of age. Patients \&lt; 7 years of age will not receive intraoral treatment with the lollipop. Instead, they will be asked to open their mouth while the covered cluster probe is held externally to treat their intraoral membranes. Each treatment (both external cheeks and intraoral buccal region) will be administered over 1 min with a Modulation Frequency 2.5Hz, Skin Conduction nS 001, and Beam Power mW 000, for a total treatment time of 3 minutes.
Study NCT06623279 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG202
Description: Method of Administration: Once unilateral subretinal injection; The duration of the study includes a 4-week screening period, enrollment visit, treatment visit and 52 weeks follow-up period, 4 more years long term follow up as an extension study.
Study NCT06621056 — intervention group
Intervention type: OTHER
Intervention: not applicable for observational research
Description: This is an observational research and has no intervention
Study NCT06730620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test preparation：Methylcholine chloroacetate for inhalation
Description: Cholinergic agonists
Study NCT06730620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference preparation：Methylcholine chloroacetate for inhalation（(Provocholin）
Description: Cholinergic agonists
Study NCT06730906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACTAID App
Description: The PACTAID app will provide real time decision support during exercise for patients with type 1 diabetes.
Study NCT06730477 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.
Study NCT05107466 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: P300 Visually evoked potential
Description: Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
Study NCT05723926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vine Filter
Description: The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
Study NCT05675800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin administered with psychological support
Study NCT05673161 — intervention group
Intervention type: OTHER
Intervention: iron
Description: iron treatment
Study NCT05648175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
Study NCT05648175 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-CBT
Description: The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
Study NCT05648175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT + Phone Call
Description: In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
Study NCT05648175 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-CBT + Phone Call
Description: In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
Study NCT05648175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT + Phone Call + Pharmacotherapy
Description: In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
Study NCT05648175 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-CBT + Phone Call + Pharmacotherapy
Description: In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
Study NCT06245447 — intervention group
Intervention type: OTHER
Intervention: Retrospective evaluation of specific brain MRI features
Description: * Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry
Study NCT06521580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Open reduction and internal fixation of those with osteopetrosis and weight bearing fractures
Study NCT05188547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video education
Description: Participants will be shown a video educating them on anesthesia and perioperative instructions.
Study NCT06190184 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study NCT06190184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
Study NCT06136507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW107
Description: experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
Study NCT05428241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches
Description: 0 - 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches
Description: 0 - 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen Saturation
Description: 0 - 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Saturation
Description: 0 - 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Total Blood Chemistry
Description: 0 and 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Total Blood Chemistry
Description: 0 and 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Adverse Event Monitoring
Description: Adverse Event Monitoring Throughout the Study
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adverse Event Monitoring
Description: Adverse Event Monitoring Throughout the Study
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Body Weight Monitoring
Description: 0 - 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Monitoring
Description: 0 - 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health
Description: 0 - 90 Days of Treatment
Study NCT05283525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health
Description: 0 - 90 Days of Treatment
Study NCT04902196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity cardiorespiratory exercise protocol
Description: During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
Study NCT04902196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high intensity cardiorespiratory exercise protocol
Description: During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
Study NCT04902196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity cardiorespiratory exercise protocol
Description: During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
Study NCT05959811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: 60 minutes yoga practice ,twice a week for 8 weeks
Study NCT04193709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Epidural Stimulation
Description: For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
Study NCT03559868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Participants will receive 3 mcg/Kg/day doses of oral digoxin
Study NCT03559868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT03559868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Participants will receive 0.15 mcg/Kg/day doses of oral digoxin
Study NCT05473741 — intervention group
Intervention type: DRUG
Intervention: Second Generation Long-Acting Injectable Antipsychotic Medications
Description: Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.